CXCR4 and idiopathic pulmonary fibrosis: Treatment with AD-114 but not small-molecule CXCR4 antagonist, AMD3100 (plerixifor, currently approved for mobilization of hematopoietic stem cells28) reduced IPF lung fibroblast invasive wound healing and collagen 1 secretion, especially in fibroblasts derived from IPF patients showing a slow progressive decline of lung function (as previously defined29).